



## HilleVax to Participate in November Investor Conferences

November 10, 2022

BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the Guggenheim Securities 4<sup>th</sup> Annual Immunology and Neurology Day and the Stifel Healthcare Conference. HIL-214, HilleVax's investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b clinical trial NEST-IN1 will be topics of discussion at both events.

### Guggenheim fireside chat details:

Date: Monday, November 14, 2022  
Time: 3:55 – 4:20 p.m. Eastern Daylight Time (EDT)  
Moderator: Seamus Fernandez  
HilleVax Participant: Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer

*Please contact your Guggenheim representative to access the session*

### Stifel presentation details:

Date: Wednesday, November 16, 2022  
Time: 8:35 – 9:05 a.m. Eastern Daylight Time (EDT)  
Moderator: Stephen Willey  
HilleVax Participant: Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer  
Webcast Link: <https://wsw.com/webcast/stifel74/hlvx/2126052>

### About HilleVax

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over \$4 billion in direct health system costs and \$60 billion in societal costs per year. The burden of norovirus falls disproportionately on young children and older adults. For more information about HilleVax, visit the company's website at <http://www.HilleVax.com>.

### Contact:

Shane Maltbie  
[IR@hillevax.com](mailto:IR@hillevax.com)  
+1-617-213-5054